Drug intelligence / Profile preview

GSI-2311

Development stage: Preclinical
Lead developer: Globin Solutions
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

GSI-2311 (also known as RcoM) is a preclinical-stage recombinant engineered heme-protein being developed by Globin Solutions. It is designed to function as a high-affinity carbon monoxide (CO) scavenger and an oxygen carrier. The drug is primarily intended for the treatment of carbon monoxide poisoning, where it works by binding and removing CO from hemoglobin and tissues to restore cellular respiration. Additionally, GSI-2311 is being explored as an artificial blood substitute (oxygen carrier) due to its ability to transport oxygen, potentially serving as a cell-free hemoglobin-based oxygen carrier (HBOC) in trauma or surgical settings.

Other names: RcoM

Targets

CO (Carbon monoxide)

Beyond the preview

Go deeper on GSI-2311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSI-2311.

Explore the full profile